Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials.

Antiviral research - 1 Feb 2026

Chou Sunwen, Minyard Alexis, Watanabe Justin

Abstract excerpt

In two recent Phase 3 clinical trials of maribavir that also involved existing standard therapies, many uncharacterized cytomegalovirus UL54 DNA polymerase genetic variants were encountered. Six UL54 mutations were selected for phenotyping, based on proximity to published resistance loci and quality of sequencing information. UL54 amino acid substitutions E949K and E949Q conferred foscarnet resistance with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic
Share to Cytomegalovirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytomegalovirus Infections

Share to DNA-Directed DNA Polymerase

Share to Drug Resistance, Viral

Share to Foscarnet

Share to Ganciclovir

Share to Organophosphonates

Source

Open in PubMed Open full text

Identifiers

PMID: 41482062
DOI: 10.1016/j.antiviral.2025.106340
PMCID: PMC13478573

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials.PMID 41482062Read ↗

Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.Semantic proximity Read ↗

Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.Semantic proximity Read ↗

Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infectionSemantic proximity Read ↗

Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.Semantic proximity Read ↗

Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.Semantic proximity Read ↗

Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.Semantic proximity Read ↗

Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance.Semantic proximity Read ↗

Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II MutantSemantic proximity Read ↗

Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.Semantic proximity Read ↗

Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing.Semantic proximity Read ↗

Drug-resistant cytomegalovirus: clinical implications of specific mutations.Semantic proximity Read ↗

Cytomegalovirus drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.